Published in Clin Epidemiol on January 19, 2011
Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ (2011) 1.61
Causes of mortality among tuberculosis and HIV co-infected patients in Chiang Rai, Northern Thailand. HIV AIDS (Auckl) (2012) 0.95
Mortality and causes of death among HIV-infected individuals in the country of Georgia: 1989-2012. AIDS Res Hum Retroviruses (2014) 0.89
Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. Glob J Health Sci (2013) 0.83
Antiretroviral Treatment Scale-Up and Tuberculosis Mortality in High TB/HIV Burden Countries: An Econometric Analysis. PLoS One (2016) 0.75
PCR-Internal Transcribed Spacer (ITS) genes sequencing and phylogenetic analysis of clinical and environmental Aspergillus species associated with HIV-TB co infected patients in a hospital in Abeokuta, southwestern Nigeria. Afr Health Sci (2016) 0.75
Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA (1999) 27.82
The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med (2003) 24.99
Financing of global health: tracking development assistance for health from 1990 to 2007. Lancet (2009) 13.41
Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS (2007) 4.52
Successful introduction of routine opt-out HIV testing in antenatal care in Botswana. J Acquir Immune Defic Syndr (2007) 3.48
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005. Clin Infect Dis (2007) 3.07
Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science (2003) 2.83
Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis (2006) 2.48
The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol (2009) 2.34
The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg (1995) 1.99
Maternal mortality associated with tuberculosis-HIV-1 co-infection in Durban, South Africa. AIDS (2001) 1.97
Examining out-of-pocket expenditure on health care in Nouna, Burkina Faso: implications for health policy. Trop Med Int Health (2002) 1.51
How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bull World Health Organ (2003) 1.43
Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: mortality at 7 years according to initial HIV status and type of TB. Int J Tuberc Lung Dis (2004) 1.35
Treatment outcome of TB/HIV positive and TB/HIV negative patients on directly observed treatment, short course (DOTS) in Sagamu, Nigeria. Niger J Med (2006) 1.31
Treatment results of DOTS in 1797 Sudanese tuberculosis patients with or without HIV co-infection. Int J Tuberc Lung Dis (2002) 1.30
Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis (2008) 1.23
The clinical burden of tuberculosis among human immunodeficiency virus-infected children in Western Kenya and the impact of combination antiretroviral treatment. Pediatr Infect Dis J (2009) 1.19
Health laboratories in the Tanga region of Tanzania: the quality of diagnostic services for malaria and other communicable diseases. Ann Trop Med Parasitol (2009) 1.18
Providing HIV care for tuberculosis patients in sub-Saharan Africa. Int J Tuberc Lung Dis (2006) 1.13
Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. Int J Tuberc Lung Dis (1998) 1.10
Household burden of malaria in South Africa and Mozambique: is there a catastrophic impact? Trop Med Int Health (2008) 1.09
Integrating tuberculosis and HIV services for people living with HIV: costs of the Zambian ProTEST Initiative. Cost Eff Resour Alloc (2008) 0.99
Prioritising between direct observation of therapy and case-finding interventions for tuberculosis: use of population impact measures. BMC Med (2006) 0.91
HIV and tuberculosis coinfection: inextricably linked liaison. J Natl Med Assoc (2007) 0.81
WHO revises upwards estimated number of TB deaths associated with HIV. BMJ (2009) 0.79
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet (2010) 12.92
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet (2010) 7.07
HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis (2010) 6.95
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46
Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ (2003) 4.38
Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ (2011) 4.19
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Current status and future prospects of epidemiology and public health training and research in the WHO African region. Int J Epidemiol (2012) 3.60
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38
The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong? PLoS Med (2005) 3.27
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19
Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS (2013) 3.17
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12
Treatment of periodontal disease for glycaemic control in people with diabetes. Cochrane Database Syst Rev (2010) 3.08
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ (2007) 3.06
Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health (2006) 3.04
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (2007) 3.04
Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med (2008) 2.97
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA (2008) 2.77
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS (2002) 2.74
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr (2005) 2.74
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis (2014) 2.65
Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction (2010) 2.65
Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ (2004) 2.63
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61
Prospects for tuberculosis elimination. Annu Rev Public Health (2012) 2.50
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis (2005) 2.48
Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med (2008) 2.44
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis (2005) 2.42
The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (2007) 2.39
Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet (2009) 2.35
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33
The association between food insecurity and mortality among HIV-infected individuals on HAART. J Acquir Immune Defic Syndr (2009) 2.31
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Lancet (2008) 2.31
Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med (2012) 2.23
History, principles, and practice of health and human rights. Lancet (2007) 2.19
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. CMAJ (2003) 2.18
Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS (2008) 2.14
Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther (2004) 2.14
AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. Lancet HIV (2015) 2.09
Food insecurity and hunger are prevalent among HIV-positive individuals in British Columbia, Canada. J Nutr (2005) 2.08
Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults. Trop Med Int Health (2012) 2.08
Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol (2012) 2.05
The Cameroon Mobile Phone SMS (CAMPS) trial: a randomized trial of text messaging versus usual care for adherence to antiretroviral therapy. PLoS One (2012) 2.05
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS (2010) 2.04
Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS (2012) 2.03
Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr (2002) 2.02
Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada. PLoS One (2012) 2.02
Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav (2012) 2.01
Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS (2006) 1.98
Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ (2009) 1.98
Childbearing intentions of HIV-positive women of reproductive age in Soweto, South Africa: the influence of expanding access to HAART in an HIV hyperendemic setting. Am J Public Health (2010) 1.95
Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr (2008) 1.94
Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis (2008) 1.93
Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. AIDS (2006) 1.92
The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials (2009) 1.92
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health (2006) 1.91
Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users. Health Place (2004) 1.90
Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS (2010) 1.88
The direct costs of HIV/AIDS care. Lancet Infect Dis (2006) 1.87
[Estimating the 2006 prevalence of HIV by gender and risk groups in Tijuana, Mexico]. Gac Med Mex (2009) 1.86
Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ (2012) 1.85
Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed. AIDS (2007) 1.85
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr (2004) 1.82
Neglected diseases, civil conflicts, and the right to health. Lancet (2007) 1.80
Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduct J (2004) 1.77
Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis (2003) 1.77